Harbour BioMed and Viva Biotech declare key coordinated effort to promote biotech new startups Kumar Jeetendra | August 1, 2020 HBM will combine its top Harbour Mice® stage H2L2 and its expertise in global research and development of innovative molecules, with Viva Biotech’s structure-based early phase drug discovery services. This complementary partnership will provide advanced biotech startups access to next generation technologies that create synergies to accelerate the route between ideation to merchandise. The incubated …
Try not to perspire it: Chilean canines track down coronavirus in beginning phases Kumar Jeetendra | August 1, 2020 Chilean police are training sniffer dogs to discover the coronavirus in people’s sweat for an early period, after a similar trial in the UK showed encouraging results. Four dogs are chosen for the initial training, a mixture of labradors and golden retrievers who game green”biodetector” jackets for their task. They are being trained at the …
US to pay $2.1 billion to Sanofi, GSK in COVID-19 antibody bargain Kumar Jeetendra | July 31, 2020 The US government will pay $2.1 billion to Sanofi SA and GlaxoSmithKline Plc to get COVID-19 vaccines to pay 50 million individuals and to underwrite the drug manufacturers’ testing and manufacturing, the companies said on Friday. The award is the biggest yet from’Operation Warp Speed’, the White House initiative aimed at accelerating access to treatments …
First coronavirus positive pet canine in US bites the dust: Report Kumar Jeetendra | July 31, 2020 A German shepherd,’Buddy’, that was the first confirmed instance of this novel coronavirus infection in a pet in america has expired, according to a report. In June, the United States Department of Agriculture’s (USDA) National Veterinary Services Laboratories (NVSL) had declared that the pet being the first pet in America testing positive for the virus …
Young children could spread COVID-19 up to older kids adults: Study Kumar Jeetendra | July 31, 2020 Washington, Jul 31 (PTI) Kids younger than five years with moderate to moderate COVID-19 have much higher levels of this novel coronavirus genetic material at the nose compared to older kids and adults, according to another study that raises concern about the reopening of schools and daycare centres across the world. The findings, published in …
Won’t benefit from COVID vaccine in pandemic: AstraZeneca Kumar Jeetendra | July 31, 2020 Pharmaceutical company AstraZeneca replicated its promise not to profit from a COVID-19 vaccine during the pandemic as it reported it was on course with late-stage trials for the treatment. Such guarantees were boosted by strong sales across its range of remedies during lockdown. Earnings jumped by 14 percent to USD 12.6 billion in the first …
Roche’s HER2 Companion Diagnostic for Breast Cancer: FDA approval Kumar Jeetendra | July 30, 2020 Roche, Basel, Switzerland, has received FDA approval for its Ventana HER2 Dual ISH DNA Probe Cocktail assay for the detection of the human epidermal growth factor receptor 2 (HER2) biomarker in breast cancer and as a companion diagnostic for Herceptin (trastuzumab) therapy. HER2 is an important biomarker sometimes found in breast cancer, and its detection …
‘Greatest obstruction’: Where can CanSino test its immunization abroad? Kumar Jeetendra | July 30, 2020 CanSino Biologics Inc, one of several companies globally attempting to create a coronavirus vaccine, should run late-stage trials overseas if it’s to remain in the race, experts say, but it has yet to declare a different country ready to help. Mid-stage trials revealed that its vaccine didn’t work also in people with immunity to a …
Johnson and Johnson begins human safety preliminaries Kumar Jeetendra | July 30, 2020 Johnson & Johnson on Thursday kicked off US human safety trials because of its COVID-19 vaccine after releasing details of a research in monkeys that showed its best-performing vaccine candidate offered strong defense in a single dose. When subjected to this virus, six out of six animals who obtained the vaccine candidate proved completely protected …
DCGI approaches Serum Institute to update convention for stage 2, 3 preliminaries of Oxford COVID-19 vaccine Kumar Jeetendra | July 30, 2020 The Subject Expert Committee (SEC) on COVID-19 that held its meeting Tuesday deliberated about the program by SII and requested that the Pune-based company to revise its own protocol to the stage 2 and 3 clinical trials, aside from needing some extra details. On Wednesday evening, SII filed a revised protocol for running the trials …
Waterloo Technology profiles Compounds in blood of COVID-19 Sufferers Kumar Jeetendra | July 29, 2020 A world-leading University of Waterloo spinoff company, that decodes blood samples for potential treatments for illnesses such as cancer and COVID-19, is expanding operations with the support of a 5-million USD investment. Bin Ma, a University of Waterloo computer engineering professor who co-founded Rapid Novor at 2015, says that the company’s technologies is the most …
Roche’s Tocilizumab neglects to meet essential end focuses for COVID-19 related pneumonia Kumar Jeetendra | July 29, 2020 Swiss Drug maker Roche on July 29 declared that its drug Actemra (Tocilizumab), which has emerged as a widely prescribed drug for treating hosiptalised COVID-19 patients, didn’t fulfill its primary endpoint of improved clinical standing in hospitalised adult patients with acute COVID-19 related pneumonia. In addition, the primary secondary endpoint of decreased patient mortality week …
